Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial-Reference-Cited by-同舟云学术

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Published:2016-09 Issue:9 Volume:4 Page:708-719
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Tashkin Donald P,Roth Michael D,Clements Philip J,Furst Daniel E,Khanna Dinesh,Kleerup Eric C,Goldin Jonathan,Arriola Edgar,Volkmann Elizabeth R,Kafaja Suzanne,Silver Richard,Steen Virginia,Strange Charlie,Wise Robert,Wigley Fredrick,Mayes Maureen,Riley David J,Hussain Sabiha,Assassi Shervin,Hsu Vivien M,Patel Bela,Phillips Kristine,Martinez Fernando,Golden Jeffrey,Connolly M Kari,Varga John,Dematte Jane,Hinchcliff Monique E,Fischer Aryeh,Swigris Jeffrey,Meehan Richard,Theodore Arthur,Simms Robert,Volkov Suncica,Schraufnagel Dean E,Scholand Mary Beth,Frech Tracy,Molitor Jerry A,Highland Kristin,Read Charles A,Fritzler Marvin J,Kim Grace Hyun J,Tseng Chi-Hong,Elashoff Robert M

Funder

National Heart, Lung, and Blood Institute (NHBLI) and the National Institutes of Health:

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database;Tyndall;Ann Rheum Dis,2010

2. Prediction of pulmonary complications and long-term survival in systemic sclerosis;Nihtyanova;Arthritis Rheumatol,2014

3. Cyclophosphamide versus placebo in scleroderma lung disease;Tashkin;N Engl J Med,2006

4. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study;Goldin;Chest,2009

5. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosophamide;Kim;Eur Radiol,2011

Cited by 812 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The 2024 British Society for Rheumatology guideline for management of systemic sclerosis;Rheumatology;2024-09-11

2. Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease;RMD Open;2024-09

3. Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial;European Respiratory Journal;2024-09

4. Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results;Current Opinion in Rheumatology;2024-08-28

5. Tuberculosis is the predominant infection in systemic sclerosis: thirty-year retrospective study of serious infections from a single centre;Rheumatology International;2024-08-24